Auspex Announces Favorable Topline Results From Thorough QT Clinical Trial of SD-809
12 janv. 2015 02h00 HE
|
Auspex Pharmaceuticals, Inc.
SD-809 Met Primary Outcome Measure, Showed No Clinically Significant QT Prolongation
NDA Submission Planned by Mid-2015
LA JOLLA, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Auspex...
Auspex to Present at the J.P. Morgan Healthcare Conference
05 janv. 2015 16h07 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Added to the NASDAQ Biotechnology Index
22 déc. 2014 16h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease
16 déc. 2014 16h05 HE
|
Auspex Pharmaceuticals, Inc.
Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated
ARC-HD Trial Shows Successful Maintenance of Chorea Control After...
Auspex to Present at the Piper Jaffray Healthcare Conference
01 déc. 2014 09h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Reports Third Quarter 2014 Results and Business Highlights
10 nov. 2014 08h30 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Huntington's Disease
06 nov. 2014 12h35 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial for SD-809 in Tardive Dyskinesia
30 oct. 2014 07h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex to Present at the Baird 2014 Healthcare Conference
27 août 2014 16h01 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel...
Auspex Pharmaceuticals Completes Enrollment in Phase 3 Registration Clinical Trial of SD-809 in Chorea Associated With Huntington's Disease
18 août 2014 07h00 HE
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Aug. 18, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late clinical stage biopharmaceutical company focused on developing and commercializing novel...